Stock analysts at StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Get Free Report) in a report released on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.
OpGen Stock Up 3.5 %
OPGN stock opened at $1.95 on Friday. The business has a fifty day moving average price of $1.84 and a 200 day moving average price of $2.54. OpGen has a fifty-two week low of $1.40 and a fifty-two week high of $9.90.
OpGen (NASDAQ:OPGN – Get Free Report) last released its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. The firm had revenue of $0.03 million for the quarter.
About OpGen
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
See Also
- Five stocks we like better than OpGen
- Why Invest in 5G? How to Invest in 5G Stocks
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Trading Halts Explained
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Time to Load Up on Home Builders?
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.
